Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.66 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469502 | 1.00 | SLC2A1 (0.66) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| SCHEMBL534435 | 0.95 | SLC2A1 (0.60) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| SCHEMBL12496080 | 0.91 | LTA4H (0.62) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| SCHEMBL23865150 | 0.89 | SLC2A1 (0.66) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| SCHEMBL8501698 | 0.87 | SLC2A1 (0.64) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| SCHEMBL8503473 | 0.87 | SLC2A1 (0.64) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| SCHEMBL8501526 | 0.87 | SLC2A1 (0.64) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| SCHEMBL8505207 | 0.87 | SLC2A1 (0.64) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| Hydrochloric Acid SCHEMBL11741891 | 0.86 | SLC2A1 (0.67) | SLC2A1NR5A1LMNAMMP9MMP8 | |
| SCHEMBL13172437 | 0.85 | NR5A1 (0.63) | SLC2A1NR5A1LMNAMMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | claimed |
| EP-3778621-B1 | PEPTIDE SYNTHESIS METHOD | JITSUBO CO LTD (JP) | 2023-08-23 | — | — | EP | claimed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | claimed |
| EP-3778621-A1 | PEPTIDE SYNTHESIS METHOD | Jitsubo Co., Ltd. (JP) | 2021-02-17 | — | — | EP | claimed |
| EP-2711370-B1 | METHOD FOR PRODUCING OLIGONUCLEOTIDES | AJINOMOTO KK (JP) | 2018-01-03 | — | — | EP | claimed |
| US-9790497-B2 | Morpholino oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2017-10-17 | — | — | US | claimed |
| US-9353148-B2 | Method for producing peptide | AJINOMOTO CO., INC. (JP) | 2016-05-31 | — | — | US | claimed |
| US-9353147-B2 | Method for producing peptide | AJINOMOTO CO., INC. (JP) | 2016-05-31 | — | — | US | claimed |
| EP-3015467-A1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | Ajinomoto Co., Inc. (JP) | 2016-05-04 | — | — | EP | claimed |
| US-20160076033-A1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2016-03-17 | — | — | US | claimed |
| US-9169187-B2 | Method of making peptides using diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2015-10-27 | — | — | US | claimed |
| US-9029528-B2 | Solution-based method of making oligonucleotides via phosphoramidite coupling | AJINOMOTO CO., INC. (JP) | 2015-05-12 | — | — | US | claimed |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC (JP) | 2014-07-31 | — | — | US | claimed |
| US-8722934-B2 | Diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2014-05-13 | — | — | US | claimed |
| US-20140088291-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-27 | — | — | US | claimed |
| EP-2711370-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-03-26 | — | — | EP | claimed |
| US-20140080999-A1 | METHOD FOR PRODUCING PEPTIDE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | claimed |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2012-11-22 | — | — | US | claimed |
| EP-2415745-A1 | DIPHENYLMETHANE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, DNPEP, QPCTL | SLC2A1 4330/4885NR5A1 2883/4885LMNA 300/4885 |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | VIP, NPPA, NGLY1 | SLC2A1 4042/4885NR5A1 2347/4885LMNA 584/4885 |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, VIP, CCKBR | SLC2A1 3858/4885NR5A1 3226/4885LMNA 310/4885 |
| US-20140080999-A1 | METHOD FOR PRODUCING PEPTIDE | VIP, ANPEP, NPPA | SLC2A1 4149/4885NR5A1 2972/4885LMNA 1014/4885 |
| US-20140088291-A1 | METHOD FOR PRODUCING PEPTIDE | ANPEP, NPPA, LNPEP | SLC2A1 4459/4885NR5A1 2104/4885LMNA 332/4885 |
| US-12351601-B2 | Method for producing peptide continuously | VIP, NPPA, NGLY1 | SLC2A1 4042/4885NR5A1 2347/4885LMNA 584/4885 |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | RNGTT, POLM, RNMT | SLC2A1 3642/4885NR5A1 2010/4885LMNA 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.